Genes of chicken MHC regulate the adherence activity of blood monocytes in Rous sarcomas progressing and regressing lines.
The influence of the chicken major histocompatibility (B) complex (MHC) on the adherence potential of monocyte-derived macrophages was examined using the congenic chicken lines CB and CC. These lines represent well-defined genetic models for the study of resistance (CB) or susceptibility (CC) to the progressive growth of Rous sarcomas. Using a monoclonal antibody specific for chicken monocytes/macrophages, CB and CC chickens were shown by flow cytometry analyses to have similar proportions of peripheral blood monocytes. However, when the glass-adherence potential of these cells was compared during incubation in tissue culture medium over 24, 48 and 72 h at 40 degrees C, significant differences were seen between cells from these two inbred lines. After 24 and 48 h, glass-adherence by CB cells was 2-3 fold higher than that of CC cells. After 72 h this difference decreased to 1.5 fold. At 24 and 48 h, the adherent CB macrophages also appeared about 1.5 times larger than those of CC chickens. Genetic analysis using F1 hybrids (CBxCC) showed that this trait is regulated by a dominant gene that segregates with the B12 haplotype in the backcross generation F1xCC. From the results obtained with the recombinant congenic lines CB.R1 and CC.R1, we conclude that the gene regulating adherence potential is localized within the B-F/L region of the chicken MHC. About 50% of adherent cells were able to phagocytose opsonised FITC-labelled Zymosan particles. The level of nitric oxide production in vitro by CB and CC macrophages was equal. The importance of cells of the mononuclear phagocyte system for the response to Rous sarcoma virus (RSV) infection was studied in CB chickens using the anti-macrophage agents silica, carrageenan, and C12MDP, encapsulated in liposomes. In those chickens treated with silica and carrageenan, we observed progressive growth of RSV-induced tumors. The graft-versus-host reactivity of peripheral blood lymphocytes (PBL) of treated chickens was comparable to controls. In vitro nitric oxide production by macrophages from silica-treated chickens was higher than by macrophages from untreated controls.
Hala
K
K
Institute for General and Experimental Pathology, University of Innsbruck, Austria. karel.hala@uibk.ac.at
Moore
C
C
Plachy
J
J
Kaspers
B
B
Böck
G
G
Hofmann
A
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001358:Avian Sarcoma Viruses / Q000276:immunology*; D002351:Carrageenan / Q000494:pharmacology / Q000627:therapeutic use; D002448:Cell Adhesion; D002645:Chickens / Q000235:genetics* / Q000276:immunology; D004002:Clodronic Acid / Q000494:pharmacology / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005260:Female; D005434:Flow Cytometry / Q000662:veterinary; D005786:Gene Expression Regulation; D006087:Graft vs Host Reaction / Q000276:immunology; D006239:Haplotypes; D008264:Macrophages / Q000166:cytology / Q000276:immunology; D008285:Major Histocompatibility Complex / Q000235:genetics* / Q000276:immunology; D008297:Male; D009000:Monocytes / Q000166:cytology / Q000276:immunology*; D009569:Nitric Oxide / Q000096:biosynthesis; D010587:Phagocytosis / Q000276:immunology; D001357:Sarcoma, Avian / Q000235:genetics* / Q000276:immunology; D012822:Silicon Dioxide / Q000494:pharmacology / Q000627:therapeutic use; D015054:Zymosan / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D004002:Clodronic Acid; D009569:Nitric Oxide; D012822:Silicon Dioxide; D002351:Carrageenan; D015054:Zymosan